Cantargia Announces Publication of Clinical Data Showing Benefit of Nadunolimab Combination Therapy in Advanced Lung Cancer
Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival of 54%
Strong efficacy signal observed in non-squamous NSCLC patients previously treated with the PD-1 inhibitor pembrolizumab, with median OS of 26.7 months and 91% ORR, including two complete responses
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced the publication of results from the CANFOUR trial with nadunolimab in combination with chemotherapy in the peer reviewed journal Lung Cancer. 40 patients with advanced NSCLC were treated with nadunolimab in combination with cisplatin/gemcitabine or carboplatin/pemetrexed for 4-6 cycles before continuing with nadunolimab as monotherapy or together with only gemcitabine or pemetrexed. The trial showed a manageable safety profile and encouraging median survival times, especially in patients with prior treatment with checkpoint inhibitors.
"These positive data published in Lung Cancer describe an important potential opportunity for nadunolimab, with possibilities to address a major unmet medical need" said Damian Marron, interim CEO of Cantargia. "We are particularly encouraged by the strong signal in the non-squamous NSCLC patients post PD-1 inhibitor treatment".
Lung cancer is one of the most common malignances worldwide and a leading cause of cancer-related deaths, with 84% of cases of the non-small cell lung cancer (NSCLC) type [1]. Immune checkpoint inhibitors targeting programmed death (ligand) 1 (PD-1/PD-L1) form part of the standard of care alongside chemotherapy for patients with advanced/metastatic NSCLC [2]. Treatment of NSCLC with immune checkpoint inhibitors can markedly improve tumor response rates and prolong survival, but not all patients respond to treatment and the development of treatment resistance is frequent [3, 4].
The CANFOUR Phase 2a trial with 40 advanced/metastatic NSCLC patients investigated nadunolimab in combination with cisplatin/gemcitabine (NCG) or carboplatin/pemetrexed (NCP) in first-line (1L), or in second-line (2L) after relapsing on pembrolizumab. Nadunolimab at doses of 1, 2.5 or 5 mg/kg were combined with chemotherapy for 4-6 cycles, followed by nadunolimab monotherapy or together with only gemcitabine or pemetrexed. Promising efficacy was reported with an OS of 13.7 months, which is observed to be better than historical references from randomized clinical trials of cisplatin/gemcitabine or platinum/pemetrexed in advanced NSCLC (median OS 10.3 and 11.3 months) [5,6].
Interestingly, highest efficacy was seen in patients previously treated with pembrolizumab (n=17) as compared to treatment naïve patients (n=23) (ORR 71% vs 44%; OS 15.7 vs 11.5 months). The 2L post-pembrolizumab patients had a markedly different tumor microenvironment at baseline with higher number of IL1RAP-positive immune cells, CD163+ macrophages, CD56+ NK cells and CD8+ T cells. Best response was seen in 2L non-squamous patients (n=11) which showed an outstanding ORR of 91%, PFS of 10.4 months and OS of 26.7 months, including two complete responders.
20 patients continued with nadunolimab monotherapy after having discontinued chemotherapy. One patient attained a complete response during monotherapy treatment, indicating a continued clinical effect of nadunolimab after completion of chemotherapy.
The combination showed a manageable safety profile with neutropenia being the most frequent reported adverse event.
The results support further investigation of the potential benefit in patients with non-squamous histology who previously progressed on immune checkpoint inhibitors, and to assess the potential benefit of continued nadunolimab monotherapy.
The publication, titled "Safety, efficacy, and analysis of biomarkers in patients with advanced non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab (CAN04) in combination with platinum doublet", by Paulus et al, is available online at the Lung Cancer | Journal | ScienceDirect.com by Elsevier and will be published Cantargia's web page.
References[1] Kratze et al. Cancer 2024 130(8) 1330-1348[2] Owen et al JCO Oncol Pract 2024 20(7) 893-898[3] Bagshi et al Ann Rev Path 2021 16 223-249[4] Jenkins et al Br J Cancer 2018 118(1) 9-16[5] Scagliotti et al J Clin Onc 2008 26(21) 3543-3551[6] Gandhi et al N Engl J Med 2018 378(22) 2078-2092
For further information, please contactDamian Marron, Interim CEOTelephone: +46 (0)46-275 62 60E-mail: damian.marron@cantargia.com
About CantargiaCantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.
About nadunolimab (CAN04)The antibody nadunolimab binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1α and IL-1β signaling. Nadunolimab can thereby counteract the IL-1 system which contributes to the immune suppressive tumor microenvironment and the development of resistance to chemotherapy. Nadunolimab is investigated in multiple clinical trials; the phase I/IIa trial CANFOUR, NCT03267316, evaluates nadunolimab in combination with standard chemotherapies in patients with pancreatic ductal adenocarcinoma (PDAC) (gemcitabine/nab-paclitaxel) or non-small cell lung cancer (NSCLC) (platinum-based chemotherapies). Positive data show durable responses for combination therapy in 73 PDAC patients, resulting in a median iPFS of 7.2 months and median OS of 13.2 months. An even higher median OS of 14.2 months was observed in a subgroup of patients with high tumor levels of IL1RAP. Strong efficacy was also observed in 40 NSCLC patients with median PFS of 7.2 months and a response rate of 55%; even higher responses were observed in non-squamous NSCLC patients. Early efficacy data from the phase 1b/2 trial TRIFOUR, NCT05181462, also shows signs of promising efficacy in TNBC with a 60% response rate for nadunolimab combined with carboplatin/gemcitabine.
AttachmentsCantargia announces publication of clinical data showing benefit of nadunolimab combination therapy in advanced lung cancer
SOURCE: Cantargia
View the original press release on ACCESS Newswire
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Trump deal with Europe underlines new standard of (at least) 15% tariffs
President Trump and European Commission President Ursula von der Leyen announced a trade deal Sunday with a range of somewhat vague plans for energy purchases and open markets but one thing crystal clear: a tariff rate of 15% on European goods. It's the latest example of a new tariff floor for Trump that has been backed by other recent deals and letters, including one with Japan this past week that also saw a 15% rate. "We'll have a straight simple tariff of anywhere between 15% and 50%," Trump asserted. Both Trump and von der Leyen highlighted the 15% rate Sunday after their meeting in Scotland. Trump claimed a 'straight-across tariff of 15%' for 'automobiles and everything else,' adding that US exports to Europe would face a 0% rate. Von der Leyen confirmed the 15% tariffs 'across the board and inclusive," adding that it would bring stability and predictability to US-Europe relations. Trump added that the deal includes hundreds of billions of dollars in new EU purchases of U.S. energy as well as military equipment. The 15% rate may get a mixed reaction in Europe after negotiators had previously pushed for free trade (or more recently a 10% rate), but it's a halving from the 30% tariffs Trump promised in a letter earlier this month. Sunday's agreement with the European Union — America's largest trading partner — comes following agreements with Vietnam, the Philippines, and Indonesia with saw tariff rates of between 19% and 20%. Only one negotiation has seen Trump agree to a tariff below 15% — a pact with the UK in May — with Treasury Secretary Scott Bessent writing earlier this month, "usually the first person who makes a deal makes the best deal." Some details unclear Trump also said Sunday that many of the remaining countries facing a deadline of August 1 would face a letter dictating rates, saying they would be be 'very universal for most' and that the European deal is 'the big one.' The president said three to four additional countries could be in for deals in the the coming days while most nations would simply get letters. In any case, the 15% baseline is a shift — even from recent weeks. Trump earlier this month said that many countries would see a rate of 'probably 10% or 15%, we haven't decided yet.' Even last Sunday, Commerce Secretary Howard Lutnick told CBS: "You should assume that the small countries... will have a baseline tariff of 10%." This new standard is also notable fulfillment of an oft-made campaign trail promise that saw the then-candidate pledge to create a "ring around the collar" of the US economy with a blanket rate of between 10% and 20%. Fulfilling that pledge — which was often dismissed as unrealistic at the time — has now become not only accepted but even a plus for markets after six months of Trump's second term have seen threats of higher duties that have reordered world trade actions. The recent announcement of the deal with Japan with a 15% tariff on goods like autos was welcomed by traders and helped fuel rises in US markets as well as the Japanese Nikkei 225, which immediately surged on the news. Japanese automakers in particular saw a jump after that deal as those companies celebrated a lowering of auto tariffs from 25% to 15%. European automakers now find themselves in a similar position. Trump, meanwhile, says he has no plans to amended his other sector specific tariffs as part of the European Union deal — even as Von der Leyen called the 15% tariffs 'inclusive." There are 50% tariffs currently levied on steel and aluminum (with planned duties at the same rate on copper), and Trump said Sunday that those tariffs are a "worldwide thing that stays the way it is." Trump also reiterated his promises of sectoral tariffs on semiconductors and pharmaceuticals to be rolled out, which could be much higher than 15% — unless Europe gets a carveout. Also on Sunday, Commerce Secretary Howard Lutnick said that a new semiconductor tariffs are nearly ready and would be unveiled in about "two weeks time." Ben Werschkul is a Washington correspondent for Yahoo Finance. Click here for political news related to business and money policies that will shape tomorrow's stock prices Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
7 minutes ago
- Yahoo
EU's von der Leyen: trade deal delivers certainty in uncertain times
PRESTWICK, Scotland (Reuters) -European Commission President Ursula von der Leyen on Sunday said a U.S. baseline tariff rate of 15% on imported EU goods would apply to cars, semiconductors and pharmaceutical goods. She also said that a zero-for-zero tariff rate had been agreed for certain strategic products, including aircraft and aircraft parts, certain chemicals, and certain generic drugs. No decision had been taken on a rate for wine and spirits, she added. "Today's deal creates certainty in uncertain times, delivers stability and predictability," von der Leyen told reporters before leaving Scotland. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Fox News
10 minutes ago
- Fox News
EU trade deal a 'homerun' for Trump and American people, Republican strategist says
A 'Fox News Live' political panel reacts to President Donald Trump's announcement of a trade deal with the European Union.